GlassScriptPhysician profile
Susan M Dykeman
NPI 1932280872
$1,788.96
in general payments reported to CMS, 2019-2025
22 companies · $463 in 2025
The $463 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $61.75 · 2021: $137 · 2022: $324 · 2023: $229 · 2024: $404 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $525.12 | 2019-2025 | |
| Corium, LLC | $256.15 | 2022-2025 | Azstarys, Azstarys |
| Merck Sharp & Dohme LLC | $161.04 | 2020-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Sobi, INC | $127.51 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $118.37 | 2022-2024 | |
| Phadia US INC. | $117.91 | 2021-2025 | Immunocap |
| Cranial Technologies, INC | $111.06 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $84.62 | 2019-2025 | Bexsero |
| Collegium Pharmaceutical, INC. | $33.38 | 2025 | Jornay Pm |
| Ipsen Biopharmaceuticals, INC | $33.33 | 2025 | Bylvay |
| Cipher Pharmaceuticals US LLC | $28.09 | 2025 | Natroba, Spinosad |
| Takeda Pharmaceuticals U.S.A., INC. | $27.69 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $21.25 | 2019 | |
| Springworks Therapeutics, INC. | $20.12 | 2025 | Gomekli |
| Sanofi Pasteur INC. | $17.99 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.35 | 2019 | |
| Genentech USA, INC. | $17.29 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.17 | 2025 | Qelbree |
| Shire North American Group INC | $15.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $13.18 | 2019 | |
| Kaleo, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Dykeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.